Zurcher Kantonalbank Zurich Cantonalbank Purchases 13,444 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 762.6% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 15,207 shares of the company’s stock after purchasing an additional 13,444 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Nurix Therapeutics were worth $317,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of NRIX. Quest Partners LLC purchased a new position in shares of Nurix Therapeutics in the 4th quarter worth $59,000. GAMMA Investing LLC lifted its holdings in shares of Nurix Therapeutics by 299.8% in the 2nd quarter. GAMMA Investing LLC now owns 4,566 shares of the company’s stock valued at $95,000 after acquiring an additional 3,424 shares during the last quarter. EntryPoint Capital LLC purchased a new position in Nurix Therapeutics in the first quarter worth about $123,000. China Universal Asset Management Co. Ltd. increased its stake in Nurix Therapeutics by 67.6% during the first quarter. China Universal Asset Management Co. Ltd. now owns 9,404 shares of the company’s stock worth $138,000 after acquiring an additional 3,793 shares during the last quarter. Finally, Jump Financial LLC bought a new stake in Nurix Therapeutics during the fourth quarter worth approximately $158,000.

Wall Street Analysts Forecast Growth

NRIX has been the subject of a number of recent research reports. Stephens began coverage on Nurix Therapeutics in a report on Tuesday, May 14th. They issued an “overweight” rating and a $20.00 target price for the company. HC Wainwright boosted their price objective on shares of Nurix Therapeutics from $19.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, June 18th. Oppenheimer increased their target price on shares of Nurix Therapeutics from $27.00 to $30.00 and gave the company an “outperform” rating in a research note on Wednesday. Truist Financial initiated coverage on shares of Nurix Therapeutics in a report on Wednesday, July 31st. They set a “buy” rating and a $36.00 price target on the stock. Finally, JPMorgan Chase & Co. raised their price objective on shares of Nurix Therapeutics from $31.00 to $34.00 and gave the stock an “overweight” rating in a research note on Monday, July 15th. One research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $27.00.

Insider Buying and Selling

In other Nurix Therapeutics news, CFO Houte Hans Van sold 20,000 shares of the firm’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $25.22, for a total transaction of $504,400.00. Following the transaction, the chief financial officer now owns 31,002 shares of the company’s stock, valued at approximately $781,870.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Nurix Therapeutics news, CFO Houte Hans Van sold 20,000 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $25.22, for a total transaction of $504,400.00. Following the sale, the chief financial officer now owns 31,002 shares of the company’s stock, valued at approximately $781,870.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Christine Ring sold 5,760 shares of the business’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $20.81, for a total value of $119,865.60. Following the completion of the transaction, the insider now directly owns 19,838 shares of the company’s stock, valued at $412,828.78. The disclosure for this sale can be found here. Insiders sold a total of 61,715 shares of company stock valued at $1,449,070 over the last three months. 7.20% of the stock is owned by company insiders.

Nurix Therapeutics Stock Performance

Shares of NASDAQ NRIX opened at $23.33 on Friday. Nurix Therapeutics, Inc. has a 52-week low of $4.22 and a 52-week high of $26.12. The firm has a market capitalization of $1.15 billion, a price-to-earnings ratio of -7.99 and a beta of 2.23. The stock has a 50 day moving average price of $22.16 and a 200 day moving average price of $17.43.

Nurix Therapeutics (NASDAQ:NRIX) last issued its earnings results on Thursday, July 11th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.08). Nurix Therapeutics had a negative return on equity of 67.78% and a negative net margin of 264.84%. The firm had revenue of $12.09 million during the quarter, compared to analysts’ expectations of $19.35 million. Analysts forecast that Nurix Therapeutics, Inc. will post -2.95 earnings per share for the current year.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.